Definitive Contract 75N93022C00056
- Not listed
- The National Institute of Allergy and Infectious Diseases awarded a delivery order valued at $2.18M to The Administrators of Tulane Educational Fund (doing business as Tulane University) on April 1, 2020, to conduct Study P223. This cost-plus-no-fee delivery order falls under the Simian Vaccine Evaluation Units indefinite delivery contract and is scheduled for completion by December 24, 2027. The work will be performed in New Orleans, Louisiana, where Tulane maintains its National Primate...
- The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $9,705,349.83 Definitive Contract to The Administrators of the Tulane Educational Fund, doing business as Tulane University, a private non-profit university in New Orleans, Louisiana. This non-severable base period contract runs from September 30, 2018 to September 29, 2019, with a completion date of July 14, 2024. The contract has a Cost No Fee pricing type...
- The Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases awarded a $645,369.00 delivery order to The Administrators of the Tulane Educational Fund, doing business as Tulane University, on August 5, 2019. The award, which is not set aside, is for the Conduct Study P209 under the Simian Vaccine Evaluation Units 2013-2020 master contract vehicle. Tulane University, a private non-profit university located in New...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $3,041,214 delivery order contract to Tulane University to conduct a study titled "CONDUCT STUDY P214". This contract is under NIAID's Simian Vaccine Evaluation Units (SVEUS) Indefinite Delivery Contract (IDC), a $146,300,000 multiple-award vehicle for preclinical research support services. The contract has a period of performance through July 23, 2026 and does not contain a set-aside designation. Tulane...
- This is a delivery order award to The Administrators Of Tulane Educational Fund, doing business as Tulane University, under the National Institute of Allergy and Infectious Diseases' (NIAID) Simian Vaccine Evaluation Units master contract. The $1,796,343 award is for a study titled "CONDUCT STUDY P217" with a period of performance through October 30, 2026. The contract does not have a set-aside designation. As a comprehensive research university, Tulane University has extensive...
- This is a federal contract award to The Administrators Of Tulane Educational Fund, doing business as Tulane University, by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency. The contract, valued at $3,675,463.09, is a delivery order under the Simian Vaccine Evaluation Units (SVEUS) major program. It does not have a set-aside designation. The contract supports NIAID's mission of advancing research to understand, prevent, and treat infectious diseases by...
- This is a federal contract award to The Administrators Of The Tulane Educational Fund, doing business as Tulane University, a private university located in New Orleans, Louisiana. The contract, with a ceiling value of $18,887,126.36, was awarded on June 1, 2017 by the National Institute of Allergy and Infectious Diseases, a component of the U.S. Department of Health and Human Services. The contract is for the establishment of a Nonhuman Primate (NHP) Core Cellular Immunology Laboratory to...
- This is a federal contract award from the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services, to The Administrators of Tulane Educational Fund, doing business as Tulane University. The contract is a delivery order under the "Simian Vaccine Evaluation Units 2013-2020" indefinite delivery contract, with a ceiling value of $9,035,728.24 and a completion date of April 30, 2022. The contract is for "Simian...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a delivery order valued at $1.49 million to The Administrators of Tulane Educational Fund, operating as Tulane University, for maintenance of nonhuman primates in an ABSL2/3 (Animal Biosafety Level 2/3) facility. This delivery order (75N93020D00007/75N93020F00002) is issued under the larger Simian Vaccine Evaluation Units (SVEUS) indefinite delivery contract and will be performed at Tulane's facility in New Orleans,...
- The National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded a $1.37 million delivery order contract to Tulane University under the agency's Preclinical Models of Infectious Diseases 2017-2024 master IDIQ. Tulane will evaluate monovalent vaccines for immunogenicity and efficacy against Venezuelan equine encephalitis and eastern equine encephalitis aerosol challenge in cynomolgus macaques, as outlined under Task Area B-10 of the IDIQ. The two-year period of...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $16.5 million cost-no-fee definitive contract to The Administrators of Tulane Educational Fund, doing business as Tulane University, for novel mucosal vaccine approaches for pneumonia. The award, made on September 23, 2022, extends through March 6, 2027, and will be performed in New Orleans, Louisiana. This contract was not subject to a set-aside designation. The work responds to NIAID's Broad Agency Announcement seeking advanced development of vaccine candidates to counter emerging infectious diseases and related biothreat agents, with the vaccine development research area originally estimating total awards up to $11 million. Tulane University, a comprehensive private research institution, brings substantial expertise to this effort through its established portfolio in infectious disease research and biomedical development. The university operates the Tulane National Prism Research Center, one of seven NIH-funded national primate research centers, and maintains extensive experience executing NIAID contracts, including a prior $22.6 million contract for cellular immunology research and multiple delivery orders under a $146.3 million indefinite delivery contract for preclinical infectious disease modeling. This mucosal vaccine contract leverages Tulane's advanced laboratory infrastructure and interdisciplinary research capabilities to address critical vaccine development needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| P00010 | Supplemental Agreement for work within scope | $0 | 3/8/26 | |
| P00009 | Supplemental Agreement for work within scope | $0 | 9/19/25 | |
| P00008 | Exercise an Option | $3.2m | 7/23/25 | |
| P00007 | Supplemental Agreement for work within scope | $0 | 6/2/25 | |
| P00006 | Supplemental Agreement for work within scope | $0 | 3/6/25 |